Condition: Non-Small Cell Lung Cancer · Sponsor: Ruijin Hospital
The purpose of this study is to explore the effectiveness of 68Ga-grazytracer PET/CT in early evaluation of neoadjuvant immunotherapy response in resectable NSCLC.
This description comes directly from the study's public registry record.
Hecheng Li, MD, PHD · 021-74370045 · lihecheng2000@hotmail.com
Always discuss trial participation with your own doctor first.
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06756217